Skip to main content
SpringerLink
Log in

Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction

  • Chapter
  • First Online:
Renin Angiotensin System and Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Pharmacologic inhibitors of the renin angiotensin aldosterone system (RAAS) have played an important role in treating and preventing a variety of cardiovascular diseases. Although mainly developed as antihypertensive agents, the life-saving benefits of inhibiting the RAAS at several steps along its neurohumoral cascade in patients with chronic heart failure and high-risk myocardial infarction have earned these compounds a central role in the pharmacologic armamentarium. This chapter will highlight proven accomplishments of various inhibitors of the RAAS and discuss optimal clinical use of these compounds individually and in combinations in both of these conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). (1987) N Engl J Med 316, 1429–1435.

    Google Scholar 

  2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. (1991) N Engl J Med 325, 293–302.

    Google Scholar 

  3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions (1992) N Engl J Med, 327, 685–691.

    Google Scholar 

  4. Jong, P., Yusuf, S., Rousseau, M.F., Ahn, S.A., and Bangdiwala, S.I. (2003) Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361, 1843–1848.

    Article  CAS  PubMed  Google Scholar 

  5. Cohn, J.N., Johnson, G., Ziesche, S., et al. (1991) A comparison of enalapril with hydralazine– isosorbide dinitrate in the treatment of chronic congestive heart failure. NEJM 325, 303–310.

    Article  CAS  PubMed  Google Scholar 

  6. Pitt, B., Poole-Wilson, P.A., Segal, R., et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial––the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582–1587.

    Article  CAS  PubMed  Google Scholar 

  7. Granger, C.B., McMurray, J.J., Yusuf, S., et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772–776.

    Article  CAS  PubMed  Google Scholar 

  8. Cohn, J.N., and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345, 1667–1675.

    Article  CAS  PubMed  Google Scholar 

  9. Pitt, B., Zannad, F., Remme, W.J., et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341, 709–717.

    Article  CAS  PubMed  Google Scholar 

  10. Juurlink, D.N., Mamdani, M.M., Lee, D.S., et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351, 543–551.

    Article  CAS  PubMed  Google Scholar 

  11. McMurray, J.J., and O‘Meara, E. (2004) Treatment of heart failure with spironolactone––trial and tribulations. N Engl J Med; 351, 526–528.

    Article  CAS  PubMed  Google Scholar 

  12. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., and Redfield M.M. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355, 251–259.

    Article  CAS  PubMed  Google Scholar 

  13. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777–781.

    Article  CAS  PubMed  Google Scholar 

  14. Massie, B.M., Carson, P.E., McMurray, J.J., et al. (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359, 2456–2467.

    Google Scholar 

  15. Cleland, J.G., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., and Taylor, J. (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27, 2338–2345.

    Article  CAS  PubMed  Google Scholar 

  16. http://clinicaltrial.gov/ct2/show/NCT00094302?term=TOPCAT&rank=1

  17. McMurray, J.J., Östergren, J., Swedberg, K., et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767–771.

    Article  CAS  PubMed  Google Scholar 

  18. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999) Lancet 353, 9–13.

    Google Scholar 

  19. Packer, M., Fowler, M.B., Roecker, E.B., et al. (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2194–2199.

    Article  PubMed  Google Scholar 

  20. MERIT-HF (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001–2007.

    Article  Google Scholar 

  21. Dickstein, K., Cohen-Solal, A., Filippatos, G., et al. (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10, 933–989.

    Article  PubMed  Google Scholar 

  22. Hunt, S.A., Abraham, W.T., Chin, M.H., et al. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112, e154–e235.

    Google Scholar 

  23. McMurray, J.J., Pfeffer, M.A., Swedberg, K., and Dzau, V.J. (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110, 3281–3288.

    Article  Google Scholar 

  24. Pfeffer, J.M., Pfeffer, M.A., and Braunwald, E. (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57, 84–95.

    CAS  PubMed  Google Scholar 

  25. Pfeffer, M.A., Pfeffer, J.M., Steinberg, C., and Finn, P. (1985) Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 72, 406–412.

    CAS  PubMed  Google Scholar 

  26. Pfeffer, M.A., Lamas, G.A., Vaughan, D.E., Parisi, A.F., and Braunwald, E. (1988) Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319, 80–86.

    Article  CAS  PubMed  Google Scholar 

  27. Sharpe, N., Smith, H., Murphy, J., and Hannan S. (1988) Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1, 255–259.

    Article  CAS  PubMed  Google Scholar 

  28. Pfeffer, M.A., Braunwald, E., Moyé, L.A., et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327, 669–677.

    Article  CAS  PubMed  Google Scholar 

  29. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. (1993) Lancet 342, 821–828.

    Google Scholar 

  30. Køber, L., Torp-Pedersen, C., Carlsen, J.E., et al. (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333, 1670–1676.

    Article  CAS  PubMed  Google Scholar 

  31. Ambrosioni, E., Borghi, C., and Magnani, B. (1995) The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332, 80–85.

    Article  CAS  PubMed  Google Scholar 

  32. Flather, M.D., Yusuf, S., Køber, L., et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575–1581.

    Article  CAS  PubMed  Google Scholar 

  33. Gruppo Italiano per lo Studio della Sopravvivenza Nell’Infarto Miocardico (GISSI)-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. (1994) Lancet 343, 1115–1122.

    PubMed  Google Scholar 

  34. Fourth International Study of Infarct Survival (ISIS-4): A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. (1995) Lancet 345, 669–685.

    Article  PubMed  Google Scholar 

  35. Chinese Cardiac Study Collaborative Group. (1995) Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1). Lancet 345, 686–687.

    Google Scholar 

  36. Antman, E.M., Anbe, D.T., Armstrong, P.W., et al. (2004) ACC/AHA guidelines for the management of patients with ST–elevation myocardial infarction––executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110 , 588–636.

    Google Scholar 

  37. Dickstein, K., and Kjekshus, J. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360, 752–760.

    Article  CAS  PubMed  Google Scholar 

  38. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349, 1893–1906.

    Article  CAS  PubMed  Google Scholar 

  39. Dargie, H.J. (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, 1385–1390.

    Article  CAS  PubMed  Google Scholar 

  40. Pitt, B., Remme, W., Zannad, F., et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348, 1309–1321.

    Article  CAS  PubMed  Google Scholar 

  41. McMurray, J.J.V., Pitt, B., Latini, R., et al. (2008) Effects of the oral renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1, 17–24.

    Article  CAS  PubMed  Google Scholar 

  42. Desai, A.S., Swedberg, K., McMurray, J.J., et al. (2007) Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 50, 1959–1966.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Marc A. Pfeffer MD, PhD

Authors
  1. Marc A. Pfeffer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc A. Pfeffer MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Puerto Rico, San Juan, 00936, U.S.A.

    Walmor C. DeMello

  2. Ochsner Clinic Foundation, Jefferson Highway 1514 , New Orleans, 70121, U.S.A.

    Edward D. Frohlich

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pfeffer, M.A. (2009). Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. In: DeMello, W., Frohlich, E. (eds) Renin Angiotensin System and Cardiovascular Disease. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60761-186-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-186-8_8

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-185-1

  • Online ISBN: 978-1-60761-186-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation